HGH

Monograph № 009

The original signal for growth repair and metabolic architecture studied across seven decades and still defining how the body builds and burns.

Sequence

191 amino acids

Half-life

~20–30 min (IV); ~3–5 hr (SC)

Route

Subcutaneous · Intramuscular

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Genentech / Eli Lilly

First recombinant synthesis, 1985

First disclosed

1956

Purified from pituitary tissue by Li & Papkoff

Regulatory status

FDA-Approved

Multiple indications; off-label use is widespread and contested

Studied for

GH Deficiency · Body Composition · Bone Density · Recovery

Also studied in aging, sarcopenia, and wound repair contexts

Mechanism

How HGH drives growth and repair

Human growth hormone does not act in isolation. It initiates a cascade – binding its receptor, triggering downstream mediators, and ultimately influencing nearly every tissue in the body. Understanding that cascade is the prerequisite for understanding both its therapeutic promise and its risks.

Growth hormone binds its receptor, dimerizes two monomers, and activates JAK2 to initiate phosphorylation of intracellular tyrosines. This is the canonical somatotropic signal from which all downstream effects originate.

Hepatic GHR activation drives IGF-1 secretion, which engages IGF-1R in muscle, bone, and connective tissue to activate PI3K/Akt/mTOR. IGF-1 mediates the majority of HGH’s anabolic effects on lean tissue.

STAT5b is the principal transcription factor downstream of JAK2, regulating IGF-1 expression, acid-labile subunit synthesis, and broader metabolic gene programs. Phosphorylated STAT5b dimers translocate to the nucleus to execute that program.

Independent of IGF-1, HGH activates hormone-sensitive lipase in adipocytes to mobilize free fatty acids from visceral and subcutaneous depots. Concurrent insulin antagonism in the liver and periphery shifts substrate utilization toward fat oxidation.

What we observe

Results tied to body changes

The observations below are drawn from peer-reviewed clinical and translational research. They describe patterns reported in studied populations and do not constitute predictions for any individual. Aeterna does not prescribe, dispense, or sell. These entries are educational in nature.

Lean Mass Accretion

Multiple controlled trials in GH-deficient adults document increases in lean body mass over 6–12 months of replacement therapy. The mechanism is IGF-1-mediated stimulation of muscle protein synthesis via mTORC1 and suppression of protein catabolism.

Effect magnitude varies with baseline GH status; gains in GH-sufficient individuals are attenuated and carry greater risk.

Reduction in Visceral Adiposity

HGH’s direct lipolytic action on adipocytes – particularly in visceral depots – is among its most consistently replicated metabolic effects. Studies in GH-deficient adults report meaningful reductions in trunk fat mass following physiological replacement.

Effect is dose-dependent. Supraphysiological dosing increases risk of fluid retention and glucose dysregulation without proportional benefit.

Bone Mineral Density

GH and IGF-1 together stimulate osteoblast activity and periosteal bone formation. Long-term replacement in GH-deficient patients is associated with improved bone mineral density, particularly at the lumbar spine and femoral neck.

Skeletal effects require sustained therapy (typically >12 months) and are most pronounced in those with documented deficiency.

Connective Tissue and Wound Repair

GHR expression in fibroblasts and chondrocytes supports collagen synthesis and extracellular matrix remodeling. Animal models and limited human data suggest accelerated wound closure and tendon repair under HGH influence, though robust RCT data in healthy adults remain sparse.

Evidence in non-deficient populations is preliminary. Extrapolation from deficiency models requires caution.

Exercise Capacity and Recovery

GH-deficient adults on replacement therapy demonstrate improvements in maximal oxygen uptake and muscle strength. The mechanism involves both increased lean mass and improved mitochondrial substrate utilization. Effects in GH-sufficient athletes are less clear and ethically contested.

Use in athletic populations without documented deficiency is prohibited by most sports governing bodies and carries meaningful health risk.

Lipid Profile Modulation

GH replacement in deficient adults is associated with reductions in LDL cholesterol and total cholesterol, alongside modest increases in HDL. These changes are thought to reflect improved hepatic lipoprotein metabolism downstream of GHR activation.

Lipid effects are secondary to metabolic normalization in deficiency states; they are not reliably reproduced in GH-sufficient individuals.

Evidence

Trials and long-term data

Seven decades of investigation have produced a substantial but uneven evidence base. The strongest data concern GH deficiency in adults and children; evidence for anti-aging and performance applications remains methodologically limited. Readers are encouraged to consult primary sources directly.

Journal of Clinical Endocrinology & Metabolism

2012

Body Composition and Metabolic Effects of Growth Hormone Replacement in Adult GH Deficiency: A 24-Month Randomized Controlled Trial

Adults with confirmed GH deficiency randomized to recombinant HGH replacement demonstrated significant reductions in fat mass and increases in lean body mass compared to placebo. Fasting lipid profiles improved, and quality-of-life scores were meaningfully higher in the treatment arm at 24 months.

8.4%

mean reduction in total fat mass at 24 months versus placebo

New England Journal of Medicine

1990

Effects of Human Growth Hormone in Men over 60 Years Old

Rudman et al. reported that GH administration in older men without documented deficiency increased lean mass and reduced fat mass over six months. The study was widely cited in anti-aging contexts, though subsequent analyses noted significant adverse effects – including fluid retention, carpal tunnel syndrome, and glucose intolerance – and cautioned against extrapolation to healthy aging populations.

14.4%

increase in lean body mass reported at 6 months; adverse effects were substantial

Annals of Internal Medicine

2007

Systematic Review: The Effects of Growth Hormone on Athletic Performance

A Cochrane-style systematic review of GH administration in recreational and competitive athletes found no significant improvement in strength or aerobic capacity despite increases in lean mass. The authors concluded that lean mass gains reflected fluid and connective tissue accretion rather than functional muscle hypertrophy, and that the risk-benefit profile did not support use in GH-sufficient individuals.

statistically significant strength gains detected across reviewed trials in GH-sufficient athletes

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

10 IU lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

1.11 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 150–500 mcg (conservative replacement protocols) [1] to 1000–2000 mcg (advanced metabolic studies) [4] ).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Week 1

200 mcg

Once daily · 18 units (0.18 mL)

Week 2

300 mcg

Once daily · 27 units (0.27 mL)

Week 3

400 mcg

Once daily · 36 units (0.36 mL)

Week 4

500 mcg

daily

Once daily · 45 units (0.45 mL)

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at −20 °C (−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Avoid freeze–thaw cycles.
Roll gently to mix until dissolved. Avoid excessive foaming during reconstitution.
Discard if solution appears cloudy, discolored, or contains particulate matter.

Side effects

What members describe

Fluid retention and peripheral edema - particularly at initiation or with dose escalation; usually transient.
Carpal tunnel syndrome - median nerve compression secondary to fluid accumulation; dose-dependent and reversible on reduction.
Insulin resistance and glucose intolerance - a direct consequence of HGH's counter-regulatory metabolic action; monitor fasting glucose and HbA1c.
Arthralgias and myalgias - joint and muscle discomfort reported in a meaningful proportion of users, particularly at higher doses.
Potential for IGF-1-driven cellular proliferation - theoretical and studied oncological risk with chronic supraphysiological exposure; not established at replacement doses but warrants monitoring.

Contradictions

Reasons to abstain

Active malignancy - HGH is contraindicated in the presence of any active cancer; IGF-1 signaling may promote tumor growth.
Diabetic retinopathy - HGH can worsen retinal pathology in patients with pre-existing diabetic eye disease.
Acute critical illness - use is contraindicated in patients with acute respiratory failure or following open-heart surgery based on increased mortality signals in early trials.
Closed epiphyses with intent for height gain - irrelevant in adults but noted for completeness in pediatric contexts.
Hypersensitivity to somatropin or any excipient in the formulation.

Synergies

What HGH pairs well with

HGH is rarely studied in isolation in clinical practice. The following pairings reflect patterns observed in the literature and in supervised clinical protocols. They are presented as educational observations, not as recommendations. Aeterna does not prescribe, dispense, or sell.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Ipamorelin / CJC-1295

GHRH analogues and GHRPs stimulate endogenous GH secretion via complementary receptor pathways. In some protocols, they are used as alternatives or adjuncts to exogenous HGH, preserving pituitary responsiveness while elevating GH pulse amplitude.

Endocrine Signaling

IGF-1 LR3

Exogenous IGF-1 LR3 extends the downstream anabolic signal of HGH, acting directly at the IGF-1 receptor in muscle and connective tissue. Some research protocols examine the combination to dissect GH-dependent from IGF-1-dependent effects.

Anabolic Signaling

BPC-157

BPC-157’s proposed tendon and connective tissue repair mechanisms may complement HGH’s collagen-stimulating effects. The pairing is observed in recovery-focused protocols, though direct interaction data are limited to animal models.

Tissue Repair

Thymosin Beta-4 (TB-500)

TB-500’s actin-sequestering and angiogenic properties address tissue repair at a cellular level distinct from HGH’s systemic anabolic signaling. The combination is studied in wound healing and musculoskeletal recovery contexts.

Recovery & Regeneration

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

Is HGH the same as the growth hormone the pituitary produces?

Recombinant human growth hormone (rhGH) is structurally identical to endogenous somatotropin – a 191-amino-acid single-chain polypeptide. Early preparations derived from cadaveric pituitary tissue were abandoned after cases of Creutzfeldt-Jakob disease; all current pharmaceutical-grade HGH is produced via recombinant DNA technology in Escherichia coli or mammalian cell lines.

Does HGH reverse aging?

The literature does not support this claim. The Rudman 1990 study, often cited in anti-aging contexts, documented body composition changes but also significant adverse effects. Subsequent systematic reviews have not established that HGH administration in GH-sufficient older adults produces meaningful improvements in functional outcomes, and long-term safety data raise concerns about oncological risk with chronic supraphysiological exposure.

What is the relationship between HGH and IGF-1?

HGH is the upstream signal; IGF-1 is the principal downstream mediator of its anabolic effects. The liver produces IGF-1 in response to GHR activation, and IGF-1 then acts on peripheral tissues via its own receptor. Serum IGF-1 is used clinically as a surrogate marker for GH axis activity and as a monitoring parameter during replacement therapy.

Why is evening injection preferred in replacement protocols?

Endogenous GH secretion is predominantly nocturnal, with the largest pulse occurring in the first hours of deep sleep. Evening subcutaneous injection approximates this physiological pattern, potentially improving receptor sensitivity and reducing the counter-regulatory metabolic effects – particularly insulin antagonism – that are more consequential during waking hours.

Can HGH cause cancer?

The relationship between HGH, IGF-1, and cancer risk is a subject of ongoing investigation. IGF-1 signaling promotes cellular proliferation and inhibits apoptosis – mechanisms that, in principle, could accelerate the growth of pre-existing malignant cells. Epidemiological data show associations between elevated IGF-1 and certain cancers (colorectal, prostate, breast). HGH is contraindicated in active malignancy. Whether replacement-dose therapy in deficient adults meaningfully increases cancer incidence remains debated; supraphysiological use carries greater theoretical risk.

How does HGH differ from GHRH analogues and secretagogues?

HGH is the hormone itself – exogenous replacement that bypasses the pituitary entirely. GHRH analogues (e.g., CJC-1295) stimulate the pituitary to produce more endogenous GH. GH secretagogues and GHRPs (e.g., Ipamorelin, GHRP-6) act on ghrelin receptors to amplify GH pulse amplitude. The distinction matters: secretagogues preserve the pulsatile, feedback-regulated nature of GH secretion; exogenous HGH does not, and can suppress endogenous production via negative feedback on the hypothalamic-pituitary axis.

In the same family

Further entries in the curriculum

Endocrine Signaling

A GHRH analogue that extends the half-life of growth hormone-releasing hormone, amplifying endogenous GH pulse amplitude without bypassing pituitary feedback. The architecture of its action is complementary to, and mechanistically distinct from, exogenous HGH.

Endocrine Signaling

Ipamorelin

A selective GHRP with a favorable side-effect profile relative to earlier secretagogues. Its selectivity for the ghrelin receptor – with minimal cortisol or prolactin stimulation – makes it a studied companion in GH axis protocols.

Anabolic Signaling

A long-acting analogue of insulin-like growth factor 1, acting directly at the IGF-1 receptor. Understanding its mechanism illuminates the downstream threshold at which HGH’s anabolic effects are ultimately expressed.

Sourcing · Independently verified

When you're ready, source thoughtfully.

Aeterna does not sell peptides. We maintain a short list of vendors evaluated for purity, third-party testing, handling, and supply consistency. The button here links directly to the vendor we currently recommend.

External link · We receive no remuneration. Verify your prescription before sourcing.